Oxidized-LDL, LOX-1 and angiogenesis
氧化 LDL、LOX-1 和血管生成
基本信息
- 批准号:7791637
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-10-01 至 2013-09-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAntibodiesApoptosisAreaArterial Fatty StreakArteriesArtsAtherosclerosisBindingBiological AssayBlood VesselsBlood capillariesCD36 geneCell ProliferationCellsCessation of lifeCholesterolChronicCoronary arteryDataDevelopmentDiabetes MellitusDiabetic RetinopathyDyslipidemiasEmbryonic DevelopmentEndothelial CellsEventExtracellular Matrix DegradationFoam CellsFunctional disorderGenerationsGenesGrowthGrowth FactorHumanHydrogen PeroxideHypertensionInflammatoryIschemiaKnock-outKnockout MiceLDL Cholesterol LipoproteinsLOX geneLeadLectinLesionLow-Density LipoproteinsMalignant NeoplasmsMediatingMicroarray AnalysisModelingMolecularMolecular BiologyMusMyocardial InfarctionNecrosisOxidation-ReductionOxidative StressOxygenPathogenesisPathologicPhysiologicalPhysiological ProcessesPlayProcessReactive Oxygen SpeciesResearchRoleSignal TransductionSignaling MoleculeSmall Interfering RNASmokingSuperoxidesTestingTissuesTrainingTubeUp-RegulationVascular Endothelial Growth FactorsWorkWound Healingangiogenesisatherogenesisbasecapillarycardiovascular risk factorcell injurycell motilitydesignexperienceinhibitor/antagonistlow density lipoprotein inhibitormacrophagematrigelmembermigrationmouse modelneovasculaturenoveloxidized LDL receptorsoxidized low density lipoproteinpreconditioningpublic health relevancereceptorresearch studyresponsescavenger receptoruptake
项目摘要
DESCRIPTION (provided by applicant):
Summary: Angiogenesis, defined as formation of new blood vessels, is a physiological process necessary for embryonic development and wound repair. Angiogenesis is also an important component of various pathologic events such as tissue ischemia, cancer, diabetic retinopathy, and chronic inflammatory states including atherosclerosis. Among the key events leading to angiogenesis is generation of reactive oxygen species (ROS) such as superoxide anions and hydrogen peroxide which play a key role in physiological and pathophysiological states. LOX-1, a lectin-like ox-LDL receptor, is responsible for binding and uptake of ox-LDL in endothelial cells. It has been well documented that the activation of LOX-1 itself can stimulate the formation of ROS and initiate a cascade of redox-sensitive signaling events. We postulate that oxidized LDL (ox-LDL) at low concentrations activates LOX-1 in endothelial cells, induces low levels of ROS release and initiates the angiogenic response. Our specific aims in this proposal are: Aim # 1: To study the effect of oxidized LDL (ox-LDL) on angiogenesis- These studies will be done in human coronary artery endothelial cells, in an aortic ring model of angiogenesis, as well as in wild-type and LOX-1 knock out (KO) mice. Aim # 2: To define the mechanisms of ox-LDL-induced angiogenic response- These studies will involve a number of specific inhibitors, LOX-1 antibody, siRNA against LOX-1, and upregulation of LOX-1, and will involve state-of-art molecular biology approaches. Further, to define the mechanism of the effects of ox-LDL, microarray technology will be utilized to identify genes that are up-regulated and down-regulated during angiogenesis. The strengths of the proposal are: 1. The PI has strong background on angiogenesis and LOX-1 research. 2. The PI has LOX-1 KO mice in his possession. 3. Availability of well trained molecular biologist well-versed in most aspects of the research. 4. One of the PI's team members has extensive experience in microarray technology. Significance: Understanding of the basis of formation of neovasculature may provide novel information on the basis of atherogenesis, especially in the development of unstable lesions. Information gained from this study may also have relevance in the development of cancers which are dependent of neovasculature for their growth.
PUBLIC HEALTH RELEVANCE:
Narrative Hardening of the arteries (also known as atherosclerosis) is the cause of heart attacks. As the area covered with atherosclerosis grows, there is formation of small new blood vessels; a process called "angiogenesis". Angiogenesis is caused in part by oxygen-derived molecules called reactive oxygen species (ROS). Our work has shown that ROS stimulate a receptor for oxidized cholesterol called LOX- 1. The proposed experiments are designed to test the concept that oxidized cholesterol at low concentration activates LOX-1, induces low levels of ROS release and initiates angiogenesis. In contrast, high concentration of ROS causes much LOX-1 expression and cell injury. To confirm the role of LOX-1 in angiogenesis, we will use specialized mice that lack the LOX-1. In the second set of experiments, we will study the underlying mechanisms of angiogenesis by examining changes in genes. Information from this study may be important in understanding the development of atherosclerosis and certain cancers that are dependent of angiogenesis.
描述(由申请人提供):
血管生成是胚胎发育和创伤修复所必需的生理过程,定义为新血管的形成。血管生成也是各种病理事件如组织缺血、癌症、糖尿病性视网膜病和慢性炎症状态(包括动脉粥样硬化)的重要组成部分。导致血管生成的关键事件之一是活性氧物质(ROS)的产生,如超氧阴离子和过氧化氢,其在生理和病理生理状态中起关键作用。LOX-1是一种凝集素样ox-LDL受体,负责ox-LDL在内皮细胞中的结合和摄取。已经充分证明LOX-1本身的激活可以刺激ROS的形成并启动氧化还原敏感性信号传导事件的级联。我们推测低浓度的氧化低密度脂蛋白(ox-LDL)激活内皮细胞中的LOX-1,诱导低水平的ROS释放并启动血管生成反应。目的1:研究氧化LDL(ox-LDL)对血管生成的影响-这些研究将在人冠状动脉内皮细胞、血管生成的主动脉环模型以及野生型和LOX-1敲除(KO)小鼠中进行。目标二:确定ox-LDL诱导血管生成反应的机制-这些研究将涉及许多特异性抑制剂、LOX-1抗体、针对LOX-1的siRNA和LOX-1的上调,并将涉及最先进的分子生物学方法。此外,为了确定ox-LDL的作用机制,将利用微阵列技术来鉴定在血管生成过程中上调和下调的基因。建议的优点是:1。PI在血管生成和LOX-1研究方面有很强的背景。2. PI拥有LOX-1 KO小鼠。3.有训练有素的分子生物学家精通研究的大多数方面。4. PI的团队成员之一在微阵列技术方面具有丰富的经验。重要性:了解新生血管形成的基础可能为动脉粥样硬化的基础提供新的信息,特别是在不稳定病变的发展中。从本研究中获得的信息也可能与依赖于新血管生长的癌症的发展相关。
公共卫生相关性:
叙述动脉硬化(也称为动脉粥样硬化)是心脏病发作的原因。随着动脉粥样硬化覆盖区域的增长,会形成新的小血管;这一过程称为“血管生成”。血管生成部分是由称为活性氧(ROS)的氧衍生分子引起的。我们的工作表明,ROS刺激一种称为LOX- 1的氧化胆固醇受体。所提出的实验旨在测试低浓度的氧化胆固醇激活LOX-1,诱导低水平的ROS释放并启动血管生成的概念。相反,高浓度的ROS导致LOX-1表达增加和细胞损伤。为了证实LOX-1在血管生成中的作用,我们将使用缺乏LOX-1的专门小鼠。在第二组实验中,我们将通过检测基因的变化来研究血管生成的潜在机制。这项研究的信息可能对理解动脉粥样硬化和某些依赖于血管生成的癌症的发展很重要。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JAWAHAR L MEHTA其他文献
JAWAHAR L MEHTA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JAWAHAR L MEHTA', 18)}}的其他基金
LOX-1, Angiogenesis and Atherosclerosis: Search for New Therapies.
LOX-1,血管生成和动脉粥样硬化:寻找新疗法。
- 批准号:
8542310 - 财政年份:2009
- 资助金额:
-- - 项目类别:
PCSK9-A novel target for the treatment of myocardial ischemia
PCSK9-治疗心肌缺血的新靶点
- 批准号:
10266760 - 财政年份:2009
- 资助金额:
-- - 项目类别:
PCSK9-A novel target for the treatment of myocardial ischemia
PCSK9-治疗心肌缺血的新靶点
- 批准号:
9896662 - 财政年份:2009
- 资助金额:
-- - 项目类别:
PCSK9-A novel target for the treatment of myocardial ischemia
PCSK9-治疗心肌缺血的新靶点
- 批准号:
10456121 - 财政年份:2009
- 资助金额:
-- - 项目类别:
LOX-1, Angiogenesis and Atherosclerosis: Search for New Therapies.
LOX-1,血管生成和动脉粥样硬化:寻找新疗法。
- 批准号:
8812715 - 财政年份:2009
- 资助金额:
-- - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
-- - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant for R&D
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
-- - 项目类别: